Premium
F4‐03‐01: The delayed start trial design to demonstrate disease modification: Background and prior experience
Author(s) -
Kieburtz Karl D.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.337
Subject(s) - rasagiline , medicine , placebo , disease , randomized controlled trial , clinical trial , psychological intervention , parkinson's disease , psychiatry , alternative medicine , pathology
verbal fluency (beta1⁄4-0.16, p<0.01), while patients with mild or no comorbidity remained generally stable. However, severity of comorbidity was not associated with a higher risk of conversion to dementia within three years. Conclusions: The severity of total comorbidity is associated with lower performance and faster decline on mental speed dependent tests, and should thus be taken into account when evaluating cognitive performance in clinical practice. However, severity of comorbidity is not associated with a higher risk of conversion to dementia.